Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1970 3
1971 1
1972 6
1973 4
1974 1
1975 4
1976 3
1977 3
1979 1
1981 2
1982 4
1983 8
1984 1
1985 1
1986 5
1987 5
1988 6
1989 7
1990 12
1991 8
1992 5
1993 5
1994 2
1995 7
1996 3
1997 3
1998 2
1999 7
2000 4
2001 6
2002 7
2003 5
2004 7
2005 7
2006 8
2007 6
2008 12
2009 8
2010 12
2011 26
2012 23
2013 20
2014 20
2015 16
2016 22
2017 30
2018 31
2019 40
2020 33
2021 36
2022 36
2023 25
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

507 results

Results by year

Filters applied: . Clear all
Page 1
Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy.
Lunning MA, Wang HL, Hu ZH, Locke FL, Siddiqi T, Jacobson CA, Ahmed S, Miklos DB, Lin Y, Hill BT, Ghobadi A, Neelapu SS, Westin J, Dieyi C, Field P, Miao H, Shahani SA, Patel A, Spooner C, Fu C, Muramoto D, Xu H, Pasquini MC. Lunning MA, et al. Among authors: westin j. Am J Hematol. 2024 May;99(5):880-889. doi: 10.1002/ajh.27283. Epub 2024 Mar 19. Am J Hematol. 2024. PMID: 38504387
Outcomes of subsequent anti-lymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7.
Ghobadi A, Munoz J, Westin JR, Locke FL, Miklos DB, Rapoport AP, Perales MA, Reagan PM, McGuirk JP, Jacobson CA, Kersten MJ, Avivi I, Peng A, Schupp M, To C, Oluwole OO. Ghobadi A, et al. Among authors: westin jr. Blood Adv. 2024 Feb 5:bloodadvances.2023011532. doi: 10.1182/bloodadvances.2023011532. Online ahead of print. Blood Adv. 2024. PMID: 38315832
Degradation trumps mutations in cancer.
Davis RE, Westin JR. Davis RE, et al. Among authors: westin jr. Science. 2024 Feb 2;383(6682):480-481. doi: 10.1126/science.adn4945. Epub 2024 Feb 1. Science. 2024. PMID: 38301021
Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement.
Lionel AC, Gurumurthi A, Fetooh A, Eldaya R, Ahmed S, Iyer SP, Nastoupil LJ, Westin J, Nair R, Fayad L, Malpica L, Tummala S, Flowers C, Neelapu SS, Wang ML, Jain P. Lionel AC, et al. Among authors: westin j. Leuk Lymphoma. 2024 May;65(5):669-673. doi: 10.1080/10428194.2024.2304622. Epub 2024 Jan 22. Leuk Lymphoma. 2024. PMID: 38248629 No abstract available.
Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy.
Jallouk AP, Kui N, Sun R, Westin JR, Steiner RE, Nair R, Nastoupil LJ, Fayad LE, Zaki AA, Hawkins M, Adkins S, Noorani M, Das K, Henderson J, Shpall EJ, Kebriaei P, Ramdial J, Flowers CR, Neelapu SS, Ahmed S, Strati P. Jallouk AP, et al. Among authors: westin jr. Haematologica. 2024 May 1;109(5):1460-1468. doi: 10.3324/haematol.2023.284453. Haematologica. 2024. PMID: 38031807 Free PMC article.
Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study.
Gordon MJ, Feng L, Strati P, Lee HJ, Hagemeister FB, Westin JR, Samaniego F, Marques-Piubelli ML, Vega Vazquez F, Parra Cuentas ER, Solis-Soto LM, Ma W, Wang J, Claret L, Averill B, Ibanez K, Fayad LE, Flowers CR, Green MR, Davis RE, Neelapu SS, Fowler NH, Nastoupil LJ. Gordon MJ, et al. Among authors: westin jr. Cancer. 2024 Mar 15;130(6):876-885. doi: 10.1002/cncr.35114. Epub 2023 Nov 20. Cancer. 2024. PMID: 37985359 Clinical Trial.
Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7).
Filosto S, Vardhanabhuti S, Canales MA, Poiré X, Lekakis LJ, de Vos S, Portell CA, Wang Z, To C, Schupp M, Poddar S, Trinh T, Warren CM, Aguilar EG, Budka J, Cheng P, Chou J, Bot A, Shen RR, Westin JR. Filosto S, et al. Among authors: westin jr. Blood Cancer Discov. 2024 Jan 8;5(1):21-33. doi: 10.1158/2643-3230.BCD-23-0112. Blood Cancer Discov. 2024. PMID: 37983485 Free PMC article.
507 results